(TERMINATED) prot# WA20500/ACT4072g: A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients with WHO or ISN Class III or IV Nephritis Due to Systemic Lu

Project: Research project

Project Details

Effective start/end date3/10/083/10/11


  • Quintiles, Inc. (WA20500/ACT4072g // WA20500/ACT4072g)
  • Genentech, Inc (WA20500/ACT4072g // WA20500/ACT4072g)